AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest… EP News Bureau Aug 11, 2025 Phase III UP-AA trial data show higher response rates than current JAK inhibitors, positioning AbbVie’s upadacitinib as a…
